<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Lipids Health Dis</journal-id><journal-id journal-id-type="iso-abbrev">Lipids Health Dis</journal-id><journal-title-group><journal-title>Lipids in Health and Disease</journal-title></journal-title-group><issn pub-type="epub">1476-511X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28245873</article-id><article-id pub-id-type="pmc">5331745</article-id><article-id pub-id-type="publisher-id">433</article-id><article-id pub-id-type="doi">10.1186/s12944-017-0433-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lee</surname><given-names>Chan Joo</given-names></name><address><email>ZANZU@yuhs.ac</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Choi</surname><given-names>Seungbum</given-names></name><address><email>seungbumc@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cheon</surname><given-names>Dong Huey</given-names></name><address><email>t13208@kist.re.kr</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Kyeong Yeon</given-names></name><address><email>t15133@kist.re.kr</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Cheon</surname><given-names>Eun Jeong</given-names></name><address><email>EJCHEON@yuhs.ac</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ann</surname><given-names>Soo-jin</given-names></name><address><email>HOPPUM@yuhs.ac</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Noh</surname><given-names>Hye-Min</given-names></name><address><email>NHM90@yuhs.ac</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Sungha</given-names></name><address><email>SHPARK0530@yuhs.ac</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Seok-Min</given-names></name><address><email>SMKANG@yuhs.ac</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Donghoon</given-names></name><address><email>CDHLYJ@yuhs.ac</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lee</surname><given-names>Ji Eun</given-names></name><address><email>jelee9137@kist.re.kr</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lee</surname><given-names>Sang-Hak</given-names></name><address><email>shl1106@yuhs.ac</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0470 5454</institution-id><institution-id institution-id-type="GRID">grid.15444.30</institution-id><institution>Division of Cardiology, Department of Internal Medicine, </institution><institution>Severance Hospital, Yonsei University College of Medicine, </institution></institution-wrap>Seoul, Korea </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0470 5454</institution-id><institution-id institution-id-type="GRID">grid.15444.30</institution-id><institution>Cardiovascular Research Institute, </institution><institution>Yonsei University College of Medicine, </institution></institution-wrap>Seoul, Korea </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0647 2973</institution-id><institution-id institution-id-type="GRID">grid.256155.0</institution-id><institution>Gachon Cardiovascular Research Institute, </institution><institution>Gachon University, </institution></institution-wrap>Incheon, Korea </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121053345</institution-id><institution-id institution-id-type="GRID">grid.35541.36</institution-id><institution>Center for Theragnosis, Biomedical Research Institute, </institution><institution>Korea Institute of Science and Technology, </institution></institution-wrap>Seoul, Korea </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0286 5954</institution-id><institution-id institution-id-type="GRID">grid.263736.5</institution-id><institution>Interdisciplinary program of Integrated Biotechnology, </institution><institution>Sogang University, </institution></institution-wrap>Seoul, Korea </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0729 3748</institution-id><institution-id institution-id-type="GRID">grid.412670.6</institution-id><institution>Department of chemistry, </institution><institution>Sookmyung Women&#x02019;s University, </institution></institution-wrap>Seoul, Korea </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>16</volume><elocation-id>49</elocation-id><history><date date-type="received"><day>15</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>14</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>The influence of lipid-lowering therapy on high-density lipoprotein (HDL) is incompletely understood. We compared the effect of two lipid-lowering strategies on HDL functions and identified some HDL-related proteins.</p></sec><sec><title>Methods</title><p>Thirty two patients were initially screened and HDLs of 21 patients were finally analyzed. Patients were randomized to receive atorvastatin 20&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;11) or atorvastatin 5&#x000a0;mg/ezetimibe 10&#x000a0;mg combination (<italic>n</italic>&#x02009;=&#x02009;10) for 8&#x000a0;weeks. The cholesterol efflux capacity and other anti-inflammatory functions were assessed based on HDLs of the participants before and after treatment. Pre-specified HDL proteins of the same HDL samples were measured.</p></sec><sec><title>Results</title><p>The post-treatment increase in cholesterol efflux capacities was similar between the groups (35.6% and 34.6% for mono-therapy and combination, respectively, <italic>p</italic>&#x02009;=&#x02009;0.60). Changes in nitric oxide (NO) production, vascular cell adhesion molecule-1 (VCAM-1) expression, and reactive oxygen species (ROS) production were similar between the groups. The baseline cholesterol efflux capacity correlated positively with apolipoprotein (apo)A1 and C3, whereas apoA1 and apoC1 showed inverse associations with VCAM-1 expression. The changes in the cholesterol efflux capacity were positively correlated with multiple HDL proteins, especially apoA2.</p></sec><sec><title>Conclusions</title><p>Two regimens increased the cholesterol efflux capacity of HDL comparably. Multiple HDL proteins, not limited to apoA1, showed a correlation with HDL functions. These results indicate that conventional lipid therapy may have additional effects on HDL functions with changes in HDL proteins.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov, number <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">NCT02942602</ext-link>.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12944-017-0433-6) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Atorvastatin calcium</kwd><kwd>Ezetimibe</kwd><kwd>Cholesterol-efflux regulatory protein</kwd><kwd>Inflammation</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003725</institution-id><institution>National Research Foundation of Korea</institution></institution-wrap></funding-source><award-id>2015M3A9B6029138</award-id><award-id>2015M3C7A1064795</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>Ji Eun</given-names></name><name><surname>Lee</surname><given-names>Sang-Hak</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003714</institution-id><institution>Korea Research Council of Fundamental Science and Technology</institution></institution-wrap></funding-source><award-id>No. CAP-12-2-KBSI</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>Sang-Hak</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>The role of high-density lipoprotein (HDL) in vascular disease is under active investigation. For instance, the cholesterol efflux capacity was reported to be inversely associated with the incidence of cardiovascular events [<xref ref-type="bibr" rid="CR1">1</xref>]. However, the clinical implication and role of the HDL function are not yet fully established. On the other hand, lowering the low-density lipoprotein-cholesterol (LDL-C) using statins has been the mainstay of pharmacologic therapy aimed at effectively reducing cardiovascular risk [<xref ref-type="bibr" rid="CR2">2</xref>]. Therefore, most of latest guidelines on lipid management have adopted statins as first-line agents [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. In a recent IMPROVE-IT trial, the application of simvastatin 40&#x000a0;mg/ezetimibe 10&#x000a0;mg combination was shown to reduce cardiovascular risk compared to using simvastatin 40&#x000a0;mg alone [<xref ref-type="bibr" rid="CR5">5</xref>]. The addition of ezetimibe 10&#x000a0;mg to ongoing statin therapy is highly effective in LDL-C-lowering. However, whether the combination of ezetimibe/statin has differential pleiotropic effect, such as modification of HDL function, compared to higher dose statin is not yet completely understood.</p><p>The progress in analytical methodology has enabled the identification of diverse proteins comprising HDL, and the list continues to grow. Although traditionally known to act in lipid transport, numerous HDL proteins now appear to be involved in other biological functions such as the acute phase response [<xref ref-type="bibr" rid="CR6">6</xref>] and inflammation [<xref ref-type="bibr" rid="CR7">7</xref>]. The differential expression of proteins including apolipoprotein (apo)C3 in a diseased condition showed alteration in other HDL function [<xref ref-type="bibr" rid="CR8">8</xref>]. Modification of HDL particles or their proteins is supposed to influence HDL function. For instance, oxidative stress and inflammation are reported to change the composition of proteins and function of HDL [<xref ref-type="bibr" rid="CR9">9</xref>]. However, current medical treatment is insufficient to inhibit atherosclerotic process related to dysfunctional HDL. Therefore, further studies of treatment focusing on HDL function would be recommended. To date, it has been reported that HDL-related proteins such as apolipoprotein E [<xref ref-type="bibr" rid="CR10">10</xref>], paraoxonase-1 [<xref ref-type="bibr" rid="CR11">11</xref>] or alpha-1 antitrypsin [<xref ref-type="bibr" rid="CR12">12</xref>] could be affected by lipid-lowering drugs.</p><p>The aim of this study was to compare the effects of two lipid-lowering strategies, atorvastatin 20&#x000a0;mg and atorvastatin 5&#x000a0;mg/ezetimibe 10&#x000a0;mg combination, on HDL functions. Therefore, we examined the influence of the drugs on HDL: the cholesterol efflux capacity, endothelial nitric oxide (NO) production, vascular cell adhesion molecule-1 (VCAM-1) expression, and production of reactive oxygen species (ROS) by macrophages. Additionally, we attempted to identify the specific HDL proteins associated with each function. Particularly, we measured apoA1, apoA2, apoC1, apoC2, and apoC3. We also examined whether the changes in the HDL functions correlate with altered HDL proteins following drug treatment.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study population</title><p>Patients who met the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy were eligible for this study. They consisted of patients who had a prior history of atherosclerotic cardiovascular disease, those who had diabetes mellitus, or high cardiovascular risk. The patients were statin-na&#x000ef;ve or had discontinued any lipid-lowering agent at least for 3&#x000a0;months before the enrollment unless they had previous cardiovascular disease. Patients were excluded if they were pregnant or breast feeding, had a history of acute cardio- or cerebro-vascular disease within 3&#x000a0;months before the study, uncontrolled hypertension or diabetes mellitus, thyroid dysfunction, serum transaminase &#x0003e;2 times the upper limit of normal, serum creatinine &#x0003e;1.5&#x000a0;mg/dL, an acute or chronic infection or inflammation, or a history of cancer or adverse events associated with test drugs including myopathy. All the patients provided written informed consent.</p></sec><sec id="Sec4"><title>Study protocol</title><p>The present study was a sub-study of an 8-week, randomized, open-label interventional study that was approved by Yonsei University Health System, Severance Hospital, Institutional Review Board (4-2013-0281). This study was actually a sub-study of a main trial as mentioned in the methods section, and we applied the clinical trial protocol that was used in the main study. Since our trial followed the protocol, which was revised after the study began, we included the flowchart of revised version of the protocol (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1). At the initial screening visit, the patients were interviewed to obtain their medical histories and then underwent laboratory assessments. Those who met the criteria for lipid-lowering therapy were subsequently randomized in a 1:1 ratio into two treatment groups for 8&#x000a0;weeks: atorvastatin 20&#x000a0;mg (Lipitor, Pfizer, New York, NY, USA) or atorvastatin/ezetimibe 5&#x000a0;mg/10&#x000a0;mg (Lipitor, Pfizer and Ezetrol, Merck &#x00026; Co., Whitehouse Station, NJ, USA). These two regimens were selected on our previous studies that showed these two regimens reduced LDL-C levels similarly [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Thirty-two patients were initially screened but 3 of them did not complete the study: 2 due to refuse to follow-up and 1 due to protocol violation. Other eight patients were excluded due to insufficient blood sampling. Because of high censoring rate in the atorvastatin monotherapy group, enrollment with unequal allocation was performed to avoid decreasing the power of the comparison. HDL function and proteins were finally analyzed in 21 patients (11 in the atorvastatin monotherapy group and 10 in the combination group; Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1).</p></sec><sec id="Sec5"><title>Blood sampling and isolation of HDL</title><p>Blood samples were collected from the patients on enrollment and after the 8-week drug treatment. The patients were instructed to fast and avoid alcohol beverages or smoking for at least 12&#x000a0;h before the collection of the samples, which were analysed within 4&#x000a0;h. All the analyses were performed by a local laboratory, certified by the Korean Society of Laboratory Medicine. The lipid levels were measured using an auto-analyzer.</p><p>HDL was isolated by ultracentrifugation described below. Briefly, 2&#x000a0;mL of serum sample was transferred into a 12&#x000a0;mL-ultracentrifuge tube (Polyallomer, Beckman Coulter Korea Ltd, Seoul, Korea) and then 0.12&#x000a0;g potassium bromide (KBr) and 0.045&#x000a0;g sucrose were added to be dissolved. Then, 2&#x000a0;mL of solution B (1&#x000a0;mL distilled water, sodium chloride [NaCl] 0.012&#x000a0;g, and KBr 0.135&#x000a0;g), 4&#x000a0;mL of solution A (distilled water 1&#x000a0;mL plus NaCl 0.012&#x000a0;g plus KBr 0.318&#x000a0;g), and 4&#x000a0;mL of distilled water were sequentially added. Ultracentrifugation was conducted using a Beckman Coulter XL-100&#x000a0;K Table Top Ultracentrifuge with a Beckman fixed-angle rotor (SW41Ti) for 18&#x000a0;h at 35,000&#x000a0;rpm. Then, the supernatant, contained the very low-density lipoprotein and LDL was removed and HDL was aspirated. The isolated HDL was subsequently desalted and concentrated with an Amicon 3&#x000a0;k Ultracentrifugal Filter device (Merck Millipore Korea, Seoul, Korea) at 3000&#x000a0;rpm at 4&#x000a0;&#x000b0;C.</p></sec><sec id="Sec6"><title>In vitro tests of HDL function</title><p>The cholesterol efflux assay was performed using a previously described method [<xref ref-type="bibr" rid="CR15">15</xref>]. Briefly, the J774 cells were plated and radiolabeled with 2&#x000a0;&#x003bc;Ci of <sup>3</sup>H-choelsterol/mL for 24&#x000a0;h. For the upregulation of adenosine triphosphate (ATP)-binding cassette transporter subfamily member A1 (ABCA1), the cells were incubated with medium containing 0.2% bovine serum albumin (BSA) and 0.3&#x000a0;mM cyclic adenosine monophosphate (cAMP) for 2&#x000a0;h. Then, the medium was changed to a medium containing 0.2% BSA and HDL for 4&#x000a0;h. The experiment was conducted by treatment the cells with acyl-coenzyme A:cholesterol acyltransferase inhibitor 2&#x000a0;&#x003bc;g/mL. The cholesterol efflux proportion was calculated using the following formula: Cholesterol efflux capacity (%)&#x02009;=&#x02009;[<sup>3</sup>H-cholesterol (&#x003bc;Ci) in medium containing HDL/(<sup>3</sup>H-cholesterol {&#x003bc;Ci} in medium containing HDL&#x02009;+&#x02009;&#x003bc;Ci of <sup>3</sup>H-cholesterol {&#x003bc;Ci} in cells)] x 100. The values were adjusted based on the efflux capacity of the pooled serum run in each plate. Each sample was run in duplicate.</p><p>The endothelial NO production was assayed as described previously [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Briefly, the human umbilical vein endothelial cells were purchased from Lonza (Basel, Switzerland), grown until the cells had reached 90% confluency, and then incubated with serum-free medium overnight. After being treated with 50&#x000a0;&#x003bc;g/mL of HDL, cells were washed and lysed in 5&#x000a0;mM Tris. After centrifuging the cell lysates, supernatants were transferred to Amicon 10&#x000a0;kDa cut-off filter tubes (Merck Millipore Korea) and further centrifuged. Then the flow-through was collected and nitrite level was measured using a kit according to manufacturer&#x02019;s instruction (Cayman Chemical, Ann Arbor, MI, USA).</p><p>The VCAM-1 level was measured by western blotting [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Briefly, the human umbilical vein endothelial cells were grown and VCAM-1 expression was induced by 5&#x000a0;ng/mL of tumor necrosis factor-&#x003b1; in serum-free media overnight. Then, the cells were treated with 50&#x000a0;&#x003bc;g/mL of HDL for 4&#x000a0;h, washed, and lysed in radioimmunoprecipitation assay buffer supplemented with protease inhibitor cocktail tablet (Roche Applied Science, Penzberg, Germany). After that, the total protein concentration of cell lysate supernatant was determined, then 7&#x000a0;&#x003bc;g of protein was loaded, and subsequently separated by running the 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were transferred from the gel to a nitrocellulose membrane and incubated with anti-VCAM-1 (Abcam, Cambridge, MA, USA) and mouse anti-&#x003b2;-actin antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Protein bands were visualized using the SuperSignal West Pico Chemiluminescent substrate (ThermoFisher Scientific, Waltham, MA, USA), and the band intensity was quantified using the ImageJ software (National Institute of Health, Bethesda, MD, USA). The VCAM-1 expression was normalized to the intensity of &#x003b2;&#x02013;actin, and the levels in cells treated with each HDL sample were presented as percentages of untreated cells.</p><p>The generation of intracellular ROS was determined using dichlorodihydrofluorescein diacetate (CM-H2DCFDA, ThermoFisher Scientific) [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. After treating J774 cells with 100&#x000a0;&#x003bc;g/mL of HDL for 24&#x000a0;h, they were stained with 5&#x000a0;&#x003bc;M CM-H2DCFDA in PBS for 24&#x000a0;min at 37&#x000a0;&#x000b0;C, incubated with or without 100&#x000a0;M hydroperoxide for 20&#x000a0;min, and then ROS generation was detected using a flow cytometer. The mean fluorescence intensity was measured in 10,000 cells using the fluorescein isothiocyanate channel.</p></sec><sec id="Sec7"><title>Measurement of selected HDL proteins</title><p>From preliminary proteomic analysis of HDL samples based on the protocol we previously reported [<xref ref-type="bibr" rid="CR22">22</xref>], we selected five HDL-related proteins that were abundantly and reproducibly detected: apoA1, apoA2, apoC1, poC2, and apoC3. The proteins were measured and quantified as follows. Briefly, the same amount (from 0.5 to 10&#x000a0;&#x003bc;g) of the HDL samples were separated by 15% SDS-PAGE and transferred onto polyvinylidene difluoride membranes, which were blocked against nonspecific binding, and then incubated with primary antibodies against apoA1, apoA2 (Santa Cruz Biotechnology), apoC1, apoC2 (Abcam), and apoC3 (Academy Bio-Medical Company Inc., Houston, TX, USA). Then, the membranes were further incubated with appropriate horseradish peroxidase-conjugated bovine anti-mouse or goat anti-rabbit secondary antibodies (Santa Cruz). The signal was detected using chemiluminescence with ECL reagent (GE Healthcare, Piscataway, NJ, USA) and the band intensities were quantified using the ImageJ software.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>The clinical and laboratory variables were compared by the Student&#x02019;s <italic>t</italic>-test or chi-square test. A paired <italic>t</italic>-test was used to compare the parameters before and after drug treatment. For the variables showing a skewed distribution, the Wilcoxon signed-rank test for the median was used. The Spearman correlation analysis was used to evaluate the association between the HDL functional parameters and HDL-related protein levels as well as the changes of HDL function and those of HDL protein levels. All the analyses used two-tailed tests with a significance level of 0.05. The statistics for the social sciences version 17.0 software (SPSS Inc, Chicago, IL, USA) was used for the analyses. This study is registered with ClinicalTrials.gov, number NCT02942602.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Clinical characteristics and laboratory values</title><p>The median age of the study patients was 57&#x000a0;years, and 18 (85%) were males, while three and 13 (14 and 62%, respectively) had diabetes and coronary artery disease, respectively. The baseline high-density lipoprotein-cholesterol (HDL-C) levels were marginally higher in the atorvastatin group than they were in the combination group (45&#x000a0;mg/dL and 39&#x000a0;mg/dL, respectively, <italic>p</italic>&#x02009;=&#x02009;0.06). The other clinical and laboratory characteristics were comparable between both groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). After the 8-week drug treatment, the LDL-C levels were reduced in both groups, and the median percentage changes were comparable (-31.6% and -31.1%, respectively, <italic>p</italic>&#x02009;=&#x02009;0.57). Although the HDL-C increased significantly only in the atorvastatin monotherapy group, the median percentage change in the HDL-C did not differ between the two groups (11.5% and 8.1%, respectively, <italic>p</italic>&#x02009;=&#x02009;0.62, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical characteristics of the study subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Atorvastatin (<italic>N</italic>&#x02009;=&#x02009;11)</th><th>Combination (<italic>N</italic>&#x02009;=&#x02009;10)</th><th>
<italic>p</italic>
</th></tr></thead><tbody><tr><td>Age, years</td><td>58 (51, 64)</td><td>57 (43, 63)</td><td>0.75</td></tr><tr><td>Male</td><td>9 (82)</td><td>9 (90)</td><td>1.00</td></tr><tr><td colspan="4">Medical history</td></tr><tr><td>&#x02003;Hypertension</td><td>8 (73)</td><td>6 (60)</td><td>0.88</td></tr><tr><td>&#x02003;Diabetes mellitus</td><td>2 (18)</td><td>1 (10)</td><td>1.00</td></tr><tr><td>&#x02003;LDL-C &#x02265;160&#x000a0;mg/dL</td><td>4 (36)</td><td>0 (0)</td><td>0.12</td></tr><tr><td>&#x02003;Smoking</td><td>7 (64)</td><td>6 (60)</td><td>1.00</td></tr><tr><td>&#x02003;Coronary artery disease</td><td>6 (55)</td><td>7 (70)</td><td>0.78</td></tr><tr><td>Body mass index, kg/m<sup>2</sup>
</td><td>24.4 (23.4, 25.6)</td><td>25.9 (23.4, 26.5)</td><td>0.44</td></tr><tr><td colspan="4">Laboratory values, mg/dL</td></tr><tr><td>&#x02003;Total cholesterol</td><td>214 (191, 261)</td><td>200 (163, 211)</td><td>0.17</td></tr><tr><td>&#x02003;Triglyceride</td><td>187 (125, 341)</td><td>120 (105, 184)</td><td>0.26</td></tr><tr><td>&#x02003;HDL-C</td><td>45 (42, 54)</td><td>39 (37, 45)</td><td>0.06</td></tr><tr><td>&#x02003;LDL-C</td><td>110 (95, 155)</td><td>134 (102, 142)</td><td>0.83</td></tr><tr><td colspan="4">Medications</td></tr><tr><td>&#x02003;Aspirin</td><td>7 (64)</td><td>7 (70)</td><td>1.00</td></tr><tr><td>&#x02003;&#x003b2;-blockers</td><td>5 (46)</td><td>4 (40)</td><td>1.00</td></tr><tr><td>&#x02003;Calcium channel blockers</td><td>3 (27)</td><td>3 (30)</td><td>1.00</td></tr><tr><td>&#x02003;RAS inhibitors</td><td>6 (55)</td><td>5 (50)</td><td>1.00</td></tr></tbody></table><table-wrap-foot><p>Variables are expressed as median (25<sup>th</sup> percentile, 75<sup>th</sup> percentile) or number (%), <italic>HDL-C</italic> high-density lipoprotein-cholesterol, <italic>LDL-C</italic> low-density lipoprotein-cholesterol, <italic>RAS</italic> renin-angiotensin system</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>Changes in HDL function after drug treatment</title><p>The baseline median cholesterol efflux capacities were similar between the atorvastatin and combination groups (13.1% and 16.4%, respectively, <italic>p</italic>&#x02009;=&#x02009;0.32) (Fig&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>). NO and ROS production, as well as VCAM-1 expression, did not differ between the two groups (Figs&#x000a0;<xref rid="Fig1" ref-type="fig">1c, e, and g</xref>). After the 8-week drug treatment, the cholesterol efflux capacity significantly increased in the atorvastatin, but not in the combination group (Fig&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>). However, the percentage change in the capacities did not differ between the groups (35.6% and 34.6%, respectively, <italic>p</italic>&#x02009;=&#x02009;0.60, Fig&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). The NO production did not change significantly after treatment in the monotherapy and combination groups (Fig&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>), and there were no inter-group difference in the percentage changes (9.5% and -5.2%, respectively, <italic>p</italic>&#x02009;=&#x02009;0.21, Fig&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref>). Furthermore, both groups exhibited no changes in the VCAM-1 expressions and ROS production after drug treatment (Figs&#x000a0;<xref rid="Fig1" ref-type="fig">1e and g</xref>). The percentage changes in the two functional parameters were similar between the monotherapy and combination groups (-5.5% and 2.4%, VCAM-1 expression, <italic>p</italic>&#x02009;=&#x02009;0.25; 3.0% and -7.2%, ROS production, <italic>p</italic>&#x02009;=&#x02009;0.43, respectively, Figs&#x000a0;<xref rid="Fig1" ref-type="fig">1f and h</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>The parameters of high-density lipoprotein (HDL) function and the percentage changes after drug treatment. <bold>a</bold> and <bold>b</bold>) Cholesterol efflux capacity, <bold>c</bold> and <bold>d</bold> nitric oxide (NO) production, <bold>e</bold> and <bold>f</bold> vascular cell adhesion molecule-1 (VCAM-1) expression, and <bold>g</bold> and <bold>h</bold> reactive oxygen species (ROS) production</p></caption><graphic xlink:href="12944_2017_433_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec12"><title>Relationship between changes in HDL function and HDL-related proteins</title><p>The baseline cholesterol efflux capacities were positively correlated with the apoA1 levels (rho&#x02009;=&#x02009;0.52, <italic>p</italic>&#x02009;=&#x02009;0.02) and apoC3 (rho&#x02009;=&#x02009;0.49, <italic>p</italic>&#x02009;=&#x02009;0.03), but not with the other HDL proteins. ApoA1 (rho&#x02009;=&#x02009;-0.73, <italic>p</italic>&#x02009;=&#x02009;0.001) and apoC1 (rho&#x02009;=&#x02009;-0.53, <italic>p</italic>&#x02009;=&#x02009;0.02) showed negative associations with the VCAM-1 expression (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), while no proteins revealed any correlation with NO or ROS production.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Correlation between the parameters of high-density lipoprotein (HDL) function and selected HDL-related proteins</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Cholesterol efflux</th><th colspan="2">NO production</th><th colspan="2">VCAM-1 expression</th><th colspan="2">ROS production</th></tr><tr><th/><th>rho</th><th>p</th><th>rho</th><th>p</th><th>rho</th><th>p</th><th>rho</th><th>p</th></tr></thead><tbody><tr><td>ApoA1</td><td>0.52</td><td>0.02</td><td>-0.10</td><td>0.71</td><td>-0.73</td><td>0.001</td><td>0.26</td><td>0.35</td></tr><tr><td>ApoA2</td><td>-0.10</td><td>0.67</td><td>0.20</td><td>0.48</td><td>0.14</td><td>0.58</td><td>0.05</td><td>0.85</td></tr><tr><td>ApoC1</td><td>0.41</td><td>0.73</td><td>0.14</td><td>0.61</td><td>-0.53</td><td>0.02</td><td>0.01</td><td>0.98</td></tr><tr><td>ApoC2</td><td>0.26</td><td>0.28</td><td>0.08</td><td>0.77</td><td>-0.38</td><td>0.12</td><td>-0.09</td><td>0.76</td></tr><tr><td>ApoC3</td><td>0.49</td><td>0.03</td><td>-0.05</td><td>0.86</td><td>-0.40</td><td>0.10</td><td>-0.04</td><td>0.89</td></tr></tbody></table><table-wrap-foot><p>
<italic>NO</italic> nitric oxide, <italic>VCAM</italic> vascular cell adhesion molecule, <italic>ROS</italic> reactive oxygen species</p></table-wrap-foot></table-wrap>
</p><p>Furthermore, drug treatment did not induce significant changes in all the investigated HDL proteins, while percentage changes in expression were similar between the two groups for each protein (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2). However, the change in the cholesterol efflux capacity had a positive correlation with those of apoA1, apoA2, apoC1, apoC2, and apoC3. In particular, the correlation between the changes in capacity and apoA2 was most obvious (rho&#x02009;=&#x02009;0.75, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). No association was found between the changes in NO production, VCAM-1 expression, or ROS production and those of each HDL protein (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Correlations between the changes in high-density lipoprotein (HDL) function and those of HDL-related proteins</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Cholesterol efflux</th><th colspan="2">NO production</th><th colspan="2">VCAM-1 expression</th><th colspan="2">ROS production</th></tr><tr><th/><th>rho</th><th>p</th><th>rho</th><th>p</th><th>rho</th><th>p</th><th>rho</th><th>p</th></tr></thead><tbody><tr><td>ApoA1</td><td>0.59</td><td>0.01</td><td>0.09</td><td>0.75</td><td>-0.31</td><td>0.22</td><td>-0.22</td><td>0.43</td></tr><tr><td>ApoA2</td><td>0.75</td><td>&#x0003c;0.001</td><td>0.11</td><td>0.70</td><td>-0.12</td><td>0.63</td><td>0.45</td><td>0.11</td></tr><tr><td>ApoC1</td><td>0.60</td><td>0.01</td><td>0.26</td><td>0.34</td><td>-0.08</td><td>0.76</td><td>-0.06</td><td>0.82</td></tr><tr><td>ApoC2</td><td>0.46</td><td>0.048</td><td>0.41</td><td>0.14</td><td>-0.32</td><td>0.21</td><td>0.46</td><td>0.10</td></tr><tr><td>ApoC3</td><td>0.59</td><td>0.01</td><td>0.31</td><td>0.29</td><td>-0.32</td><td>0.20</td><td>0.41</td><td>0.15</td></tr></tbody></table><table-wrap-foot><p>
<italic>NO</italic> nitric oxide, <italic>VCAM</italic> vascular cell adhesion molecule, <italic>ROS</italic> reactive oxygen species</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec13"><title>Discussion</title><p>The following were the major findings of the present study. 1) The increase in HDL-dependent cholesterol efflux capacity was similar in the two groups. 2) Both regimens did not change the effect of HDL on NO production, VCAM-1 expression, or ROS production. 3) The cholesterol efflux capacity was positively associated with apoA1 and apoC3, whereas apoA1 and apoC1 revealed a negative correlation with VCAM-1 expression. 4) The change in cholesterol efflux capacity induced by the drug treatment was linked to the changes in multiple HDL proteins, including apoA2. To the best of our knowledge, this study is the first to report the effect of a statin/ezetimibe combination and compare two statin-based regimens on HDL function. Furthermore, the relationship between drug-induced changes in HDL function and proteins shown in our study may provide an insight into the additional pleiotropic effect of the current lipid-lowering therapy.</p><p>A few studies have shown that statins can increase HDL-dependent cholesterol efflux capacity, including a 14% with simvastatin 40&#x000a0;mg [<xref ref-type="bibr" rid="CR23">23</xref>] and by 9% with pitavastatin 2&#x000a0;mg [<xref ref-type="bibr" rid="CR11">11</xref>]. However, it was recently reported that atorvastatin did not affect cholesterol efflux capacity in studies using the sera of mice [<xref ref-type="bibr" rid="CR24">24</xref>] or human [<xref ref-type="bibr" rid="CR25">25</xref>]. The reason for the inconsistency in the statin effect on this HDL function is not clear yet. Interestingly, the cholesterol efflux has been shown to increase in studies with statin-induced increase in HDL-C [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], whereas it decreased when statins lowered HDL-C [<xref ref-type="bibr" rid="CR24">24</xref>]. In our study, HDL-C was raised, although not significantly, in both groups. However, we used the same concentration of isolated HDL from each subject and, therefore, the drug effect on the HDL concentration might have been minimized by our method, and the changes in HDL function were possibly due to differences in HDL itself.</p><p>Ezetimibe has been known to enhance reverse cholesterol transport and faecal cholesterol excretion [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Nevertheless, data on the effect of ezetimibe on HDL function including cholesterol efflux capacity is extremely limited. Recently, it was reported in hamsters that ezetimibe did not change the efflux capacity of the serum after the adjustment of HDL-C levels [<xref ref-type="bibr" rid="CR27">27</xref>]. Combination therapy with atorvastatin/ezetimibe has induced percentage changes in the cholesterol efflux capacity similar to that induced by atorvastatin monotherapy. However, several points have not been clearly understood by our results. 1) It is not clear whether the increased efflux capacity induced by drug treatment is largely caused by a primary effect on HDL or secondary effect induced by changes in the lipid metabolism. 2) Furthermore, if the observed change is due to a direct effect on HDL, we are not certain if this is attributable to the effects of ezetimibe or low-dose atorvastatin.</p><p>The two different regimens used in our study did not affect the anti-inflammatory function of HDL, whereas they enhanced the cholesterol efflux. Studies evaluating the relationship between HDL proteins and HDL functions, particularly anti-inflammatory, have been highly limited. These present results are in agreement with those of Triolo et al. [<xref ref-type="bibr" rid="CR23">23</xref>] who evaluated the effect of simvastatin. Gordon et al. [<xref ref-type="bibr" rid="CR12">12</xref>] reported that rosuvastatin increased HDL-related &#x003b1;1-antitrypsin that reduces the production of tumor necrosis factor-&#x003b1;. In addition, Green et al. [<xref ref-type="bibr" rid="CR10">10</xref>] found that statin/niacin combination reduced HDL-related apoE. Meanwhile, Miyamoto-Sasaki et al. [<xref ref-type="bibr" rid="CR11">11</xref>] revealed that HDL-associated paraoxonase-1 was increased by pitavastatin. Although we did not focus on paraoxonase-1, this enzyme is known to suppress proinflammatory response and ROS production [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], and act as one of the key HDL-related proteins.</p><p>To date, insufficient amount of data exists on the effects of the drugs on HDL proteins and their relations to biological function. In the present study, we evaluated the correlations between the changes in HDL functions and proteins and identified some relationships. Above all, the effect of apoA1 on the functions of HDL observed in our study was very similar to previously reported data. ApoA1 is a major HDL-related protein [<xref ref-type="bibr" rid="CR6">6</xref>], which is known to be critical for cholesterol efflux [<xref ref-type="bibr" rid="CR30">30</xref>]. Moreover, apoA1 was required for reconstituted HDL to inhibit the expression of cell adhesion molecules [<xref ref-type="bibr" rid="CR31">31</xref>]. In the present study, we discovered that the changes in apoA2 correlated with drug-induced changes in the cholesterol efflux capacity. It was demonstrated that HDL particles containing apoA2 without apoA1 effectively enhanced the cholesterol efflux [<xref ref-type="bibr" rid="CR32">32</xref>]. In addition, the ability of free apoA2 to promote cholesterol efflux was also reported [<xref ref-type="bibr" rid="CR33">33</xref>] while Remaley et al. [<xref ref-type="bibr" rid="CR34">34</xref>] and Sankaranarayanan et al. [<xref ref-type="bibr" rid="CR35">35</xref>] showed that apoA2 plays a role in the ABCA1- and ABCG1-mediated cholesterol efflux, respectively. However, the effect of drug treatment on apoA2 and its influence on HDL has not been shown before. Therefore, our results on apoA2 may provide an insight into the additive effect of lipid-modifying agent that is mediated, at least partly, by HDL-related proteins.</p><p>ApoC1 was negatively correlated with the endothelial VCAM-1 expression in our study. Studies regarding investigating the biological role of apoC1 have been very limited, and the results were inconsistent. It has been demonstrated that apoC1 increased the lipopolysaccharide-induced inflammation [<xref ref-type="bibr" rid="CR36">36</xref>]. Conversely, apoC1 was reported to inhibit pro-inflammatory cytokine production in murine immune cells [<xref ref-type="bibr" rid="CR37">37</xref>]. Interestingly, the inhibitory effect of HDL on LPS-induced inflammation was reduced in lecithin-cholesterol acyltransferase (LCAT)-deficient mice [<xref ref-type="bibr" rid="CR38">38</xref>]. It is well known that apoC1 activates LCAT, which is needed for HDL maturation [<xref ref-type="bibr" rid="CR39">39</xref>]. Based on this background, apoC1 may affect vascular inflammation by LCAT activation and HDL maturation. The role of apoC3 in HDL function has not been completely established. Only recently, proteomic analysis of murine HDL identified the correlation between cholesterol efflux capacity and apoC3 [<xref ref-type="bibr" rid="CR40">40</xref>]. Our study also discovered this association in human HDLs. Although its clinical relevance is not entirely clear currently, this association was also validated by the relationship observed between the changes in apoC3 and those of the cholesterol efflux in our study.</p><p>Our study had some potential limitations. First, we suggested the effect of HDL proteins and the correlations between the drug-induced changes in these proteins and functional changes in the HDL based on systemic analyses. However, the mechanism underlying the biological role of HDL proteins in HDL functions may not have been completely elucidated by this study. Future studies on the proteins that determine the drug-induced changes in HDL function may provide further insights. Second, we chose candidate proteins based on abundancy and reproducibility of the measurement. Nevertheless, numerous other proteins that have been currently reported may have additional effects on the HDL function. For instance, we cannot rule out the potential of the anti-inflammatory HDL-associated enzymes, which may have played a specific role in the in vitro tests we performed. Third, the drug effect shown by in vitro experiment may not be extrapolated to in vivo or clinical outcomes. For a more comprehensive understanding, testing the drug effect in both hepatocytes and other peripheral cells might be helpful. Finally, total number of our subjects was not sufficiently large. However, when designing this study, we referred to those of prior reports that showed drugs-induced changes of cholesterol efflux in relatively small groups of patients [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec14"><title>Conclusion</title><p>Taken together, these results suggest that atorvastatin monotherapy and the low-dose atorvastatin/ezetimibe combination similarly promoted the HDL-dependent cholesterol efflux capacity. Furthermore, the HDL-related proteins, including but not limited to apoA1, showed correlations with drug-induced changes as well as the baseline function of HDL. Our study indicates that conventional lipid-lowering therapy may have additional pleiotropic effect on HDL function, at least partly, by the changes of HDL proteins.</p></sec></body><back><app-group><app id="App1"><sec id="Sec15"><title>Additional file</title><p>
<media position="anchor" xlink:href="12944_2017_433_MOESM1_ESM.zip" id="MOESM1"><label>Additional file 1: Table S1.</label><caption><p>Changes in lipid profiles after 8-week drug treatment. <bold>Figure S1.</bold> CONSORT 2010 flow diagram. <bold>Figure S2.</bold> Expression of high-density lipoprotein (HDL)-related proteins before and after drug treatment. (A) ApoA-I, (B) ApoA-II, (C) ApoC-I, (D) ApoC-II, (E) ApoC-III. (ZIP 353 kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>ABCA1</term><def><p>Adenosine triphosphate binding cassette transporter subfamily member A1</p></def></def-item><def-item><term>BSA</term><def><p>Bovine serum albumin</p></def></def-item><def-item><term>cAMP</term><def><p>cyclic adenosine monophosphate</p></def></def-item><def-item><term>CM-H2DCFDA</term><def><p>Dichlorodihydrofluorescein diacetate</p></def></def-item><def-item><term>HDL</term><def><p>High-density lipoprotein</p></def></def-item><def-item><term>HDL-C</term><def><p>baseline high-density lipoprotein-cholesterol</p></def></def-item><def-item><term>LDL-C</term><def><p>Low-density lipoprotein-cholesterol</p></def></def-item><def-item><term>NO</term><def><p>Nitric oxide</p></def></def-item><def-item><term>ROS</term><def><p>Reactive oxygen species</p></def></def-item><def-item><term>SDS-PAGE</term><def><p>Sodium dodecyl sulphate-polyacrylamide gel electrophoresis</p></def></def-item><def-item><term>VCAM-1</term><def><p>Vascular cell adhesion molecule-1</p></def></def-item></def-list></glossary><ack><title>Acknowledgement</title><p>Not applicable.</p><sec id="FPar1"><title>Funding</title><p>This research was financially supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2012R1A4A1029061 and 2014R1A1A2056104) (SHL); the Bio &#x00026; Medical Technology Development Program of the NRF funded by the Korean Government, MSIP (2015M3A9B6029138) (SHL); the National Research Council of Science &#x00026; Technology (NST) grant by the Korean government (MSIP) (No. CAP-12-2-KBSI) (SHL); the Brain Research Program through the National Research Foundation of Korea (KRF) funded by the Ministry of Science, ICT &#x00026; Future Planning (2015M3C7A1064795) (JEL); and a KIST institutional program (JEL).</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>All data generated or analysed during this study are included in this published article.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>This study was designed by SHL and JEL; SJA isolated HDL samples; SC, EJC, SJA and HMN evaluated the functions of HDL; DHC, KYK and JEL measured selected HDL-related proteins; CJL, SP and SHL analyzed data; CJL, SC and SHL wrote the article; SMK, DC and JEL reviewed and revised the article. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>All participants gave their written informed consent Yonsei University Health System, Severance Hospital, Institutional Review Board approved the study (4-2013-0281).</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohatgi</surname><given-names>A</given-names></name><name><surname>Khera</surname><given-names>A</given-names></name><name><surname>Berry</surname><given-names>JD</given-names></name><name><surname>Givens</surname><given-names>EG</given-names></name><name><surname>Ayers</surname><given-names>CR</given-names></name><name><surname>Wedin</surname><given-names>KE</given-names></name><etal/></person-group><article-title>HDL cholesterol efflux capacity and incident cardiovascular events</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><fpage>2383</fpage><lpage>2393</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1409065</pub-id><pub-id pub-id-type="pmid">25404125</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baigent</surname><given-names>C</given-names></name><name><surname>Blackwell</surname><given-names>L</given-names></name><name><surname>Emberson</surname><given-names>J</given-names></name><name><surname>Holland</surname><given-names>LE</given-names></name><name><surname>Reith</surname><given-names>C</given-names></name><name><surname>Bhala</surname><given-names>N</given-names></name><etal/></person-group><article-title>Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials</article-title><source>Lancet</source><year>2010</year><volume>376</volume><fpage>1670</fpage><lpage>1681</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)61350-5</pub-id><pub-id pub-id-type="pmid">21067804</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiner</surname><given-names>Z</given-names></name><name><surname>Catapano</surname><given-names>AL</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Graham</surname><given-names>I</given-names></name><name><surname>Taskinen</surname><given-names>MR</given-names></name><name><surname>Wiklund</surname><given-names>O</given-names></name><etal/></person-group><article-title>ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><fpage>1769</fpage><lpage>1818</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehr158</pub-id><pub-id pub-id-type="pmid">21712404</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>NJ</given-names></name><name><surname>Robinson</surname><given-names>JG</given-names></name><name><surname>Lichtenstein</surname><given-names>AH</given-names></name><name><surname>Bairey Merz</surname><given-names>CN</given-names></name><name><surname>Blum</surname><given-names>CB</given-names></name><name><surname>Eckel</surname><given-names>RH</given-names></name><etal/></person-group><article-title>2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</article-title><source>Circulation</source><year>2014</year><volume>129</volume><fpage>S1</fpage><lpage>S45</lpage><pub-id pub-id-type="doi">10.1161/01.cir.0000437738.63853.7a</pub-id><pub-id pub-id-type="pmid">24222016</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Blazing</surname><given-names>MA</given-names></name><name><surname>Giugliano</surname><given-names>RP</given-names></name><name><surname>McCagg</surname><given-names>A</given-names></name><name><surname>White</surname><given-names>JA</given-names></name><name><surname>Theroux</surname><given-names>P</given-names></name><etal/></person-group><article-title>Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><fpage>2387</fpage><lpage>2397</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1410489</pub-id><pub-id pub-id-type="pmid">26039521</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>AS</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Long</surname><given-names>JL</given-names></name><name><surname>Davidson</surname><given-names>WS</given-names></name></person-group><article-title>Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond</article-title><source>J Lipid Res</source><year>2013</year><volume>54</volume><fpage>2575</fpage><lpage>2585</lpage><pub-id pub-id-type="doi">10.1194/jlr.R035725</pub-id><pub-id pub-id-type="pmid">23434634</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaisar</surname><given-names>T</given-names></name><name><surname>Pennathur</surname><given-names>S</given-names></name><name><surname>Green</surname><given-names>PS</given-names></name><name><surname>Gharib</surname><given-names>SA</given-names></name><name><surname>Hoofnagle</surname><given-names>AN</given-names></name><name><surname>Cheung</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL</article-title><source>J Clin Invest</source><year>2007</year><volume>117</volume><fpage>746</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1172/JCI26206</pub-id><pub-id pub-id-type="pmid">17332893</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riwanto</surname><given-names>M</given-names></name><name><surname>Rohrer</surname><given-names>L</given-names></name><name><surname>Roschitzki</surname><given-names>B</given-names></name><name><surname>Besler</surname><given-names>C</given-names></name><name><surname>Mocharla</surname><given-names>P</given-names></name><name><surname>Mueller</surname><given-names>M</given-names></name><etal/></person-group><article-title>Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling</article-title><source>Circulation</source><year>2013</year><volume>127</volume><fpage>891</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.108753</pub-id><pub-id pub-id-type="pmid">23349247</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>DiDonato</surname><given-names>JA</given-names></name><name><surname>Levison</surname><given-names>BS</given-names></name><name><surname>Schmitt</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>An abundant dysfunctional apolipoprotein A1 in human atheroma</article-title><source>Nat Med</source><year>2014</year><volume>20</volume><fpage>193</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1038/nm.3459</pub-id><pub-id pub-id-type="pmid">24464187</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>PS</given-names></name><name><surname>Vaisar</surname><given-names>T</given-names></name><name><surname>Pennathur</surname><given-names>S</given-names></name><name><surname>Kulstad</surname><given-names>JJ</given-names></name><name><surname>Moore</surname><given-names>AB</given-names></name><name><surname>Marcovina</surname><given-names>S</given-names></name><etal/></person-group><article-title>Combined statin and niacin therapy remodels the high-density lipoprotein proteome</article-title><source>Circulation</source><year>2008</year><volume>118</volume><fpage>1259</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.770669</pub-id><pub-id pub-id-type="pmid">18765395</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto-Sasaki</surname><given-names>M</given-names></name><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Monguchi</surname><given-names>T</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Toh</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients</article-title><source>J Atheroscler Thromb</source><year>2013</year><volume>20</volume><fpage>708</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.5551/jat.17210</pub-id><pub-id pub-id-type="pmid">23739642</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>SM</given-names></name><name><surname>McKenzie</surname><given-names>B</given-names></name><name><surname>Kemeh</surname><given-names>G</given-names></name><name><surname>Sampson</surname><given-names>M</given-names></name><name><surname>Perl</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>NS</given-names></name><etal/></person-group><article-title>Rosuvastatin Alters the Proteome of High Density Lipoproteins: Generation of alpha-1-antitrypsin Enriched Particles with Anti-inflammatory Properties</article-title><source>Mol Cell Proteomics</source><year>2015</year><volume>14</volume><fpage>3247</fpage><lpage>3257</lpage><pub-id pub-id-type="doi">10.1074/mcp.M115.054031</pub-id><pub-id pub-id-type="pmid">26483418</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Her</surname><given-names>AY</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name><name><surname>Choi</surname><given-names>D</given-names></name><name><surname>Jang</surname><given-names>Y</given-names></name><name><surname>Chung</surname><given-names>N</given-names></name><etal/></person-group><article-title>Effects of atorvastatin 20&#x000a0;mg, rosuvastatin 10&#x000a0;mg, and atorvastatin/ezetimibe 5&#x000a0;mg/5&#x000a0;mg on lipoproteins and glucose metabolism</article-title><source>J Cardiovasc Pharmacol Ther</source><year>2010</year><volume>15</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1177/1074248409357922</pub-id><pub-id pub-id-type="pmid">20147603</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Jang</surname><given-names>Y</given-names></name><name><surname>Chung</surname><given-names>N</given-names></name><name><surname>Choi</surname><given-names>D</given-names></name></person-group><article-title>The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A(2)</article-title><source>Clin Cardiol</source><year>2011</year><volume>34</volume><fpage>108</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1002/clc.20853</pub-id><pub-id pub-id-type="pmid">21298654</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khera</surname><given-names>AV</given-names></name><name><surname>Cuchel</surname><given-names>M</given-names></name><name><surname>de la Llera-Moya</surname><given-names>M</given-names></name><name><surname>Rodrigues</surname><given-names>A</given-names></name><name><surname>Burke</surname><given-names>MF</given-names></name><name><surname>Jafri</surname><given-names>K</given-names></name><etal/></person-group><article-title>Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><fpage>127</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1001689</pub-id><pub-id pub-id-type="pmid">21226578</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermenegildo</surname><given-names>C</given-names></name><name><surname>Medina</surname><given-names>P</given-names></name><name><surname>Peir&#x000f3;</surname><given-names>M</given-names></name><name><surname>Segarra</surname><given-names>G</given-names></name><name><surname>Vila</surname><given-names>JM</given-names></name><name><surname>Ortega</surname><given-names>J</given-names></name><etal/></person-group><article-title>Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><fpage>5636</fpage><lpage>5640</lpage><pub-id pub-id-type="doi">10.1210/jc.2002-020905</pub-id><pub-id pub-id-type="pmid">12466365</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seto</surname><given-names>SW</given-names></name><name><surname>Krishna</surname><given-names>SM</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Khosla</surname><given-names>S</given-names></name><name><surname>Golledge</surname><given-names>J</given-names></name></person-group><article-title>Impaired acetylcholine-induced endothelium-dependent aortic relaxation by caveolin-1 in angiotensin II-infused apolipoprotein-E (ApoE-/-) knockout mice</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e58481</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0058481</pub-id><pub-id pub-id-type="pmid">23469284</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speer</surname><given-names>T</given-names></name><name><surname>Rohrer</surname><given-names>L</given-names></name><name><surname>Blyszczuk</surname><given-names>P</given-names></name><name><surname>Shroff</surname><given-names>R</given-names></name><name><surname>Kuschnerus</surname><given-names>K</given-names></name><name><surname>Kr&#x000e4;nkel</surname><given-names>N</given-names></name><etal/></person-group><article-title>Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2</article-title><source>Immunity</source><year>2013</year><volume>38</volume><fpage>754</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.02.009</pub-id><pub-id pub-id-type="pmid">23477738</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shroff</surname><given-names>R</given-names></name><name><surname>Speer</surname><given-names>T</given-names></name><name><surname>Colin</surname><given-names>S</given-names></name><name><surname>Charakida</surname><given-names>M</given-names></name><name><surname>Zewinger</surname><given-names>S</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name><etal/></person-group><article-title>HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype</article-title><source>J Am Soc Nephrol</source><year>2014</year><volume>25</volume><fpage>2658</fpage><lpage>2668</lpage><pub-id pub-id-type="doi">10.1681/ASN.2013111212</pub-id><pub-id pub-id-type="pmid">24854267</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Ke</surname><given-names>G</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><etal/></person-group><article-title>Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: involvement of a mitochondria-reactive oxygen species pathway</article-title><source>Diabetes</source><year>2009</year><volume>58</volume><fpage>954</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.2337/db07-1524</pub-id><pub-id pub-id-type="pmid">19188429</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>JY</given-names></name><name><surname>Tian</surname><given-names>XY</given-names></name><name><surname>Cheang</surname><given-names>WS</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Upregulation of Angiotensin (1-7)-Mediated Signaling Preserves Endothelial Function Through Reducing Oxidative Stress in Diabetes</article-title><source>Antioxid Redox Signal</source><year>2015</year><volume>23</volume><fpage>880</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1089/ars.2014.6070</pub-id><pub-id pub-id-type="pmid">25867182</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheon</surname><given-names>DH</given-names></name><name><surname>Nam</surname><given-names>EJ</given-names></name><name><surname>Park</surname><given-names>KH</given-names></name><name><surname>Woo</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Comprehensive Analysis of Low-Molecular-Weight Human Plasma Proteome Using Top-Down Mass Spectrometry</article-title><source>J Proteome Res</source><year>2016</year><volume>15</volume><fpage>229</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.5b00773</pub-id><pub-id pub-id-type="pmid">26576621</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Triolo</surname><given-names>M</given-names></name><name><surname>Annema</surname><given-names>W</given-names></name><name><surname>de Boer</surname><given-names>JF</given-names></name><name><surname>Tietge</surname><given-names>UJ</given-names></name><name><surname>Dullaart</surname><given-names>RP</given-names></name></person-group><article-title>Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes</article-title><source>Eur J Clin Invest</source><year>2014</year><volume>44</volume><fpage>240</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1111/eci.12226</pub-id><pub-id pub-id-type="pmid">24325778</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Miura</surname><given-names>S</given-names></name><name><surname>Tanigawa</surname><given-names>H</given-names></name><name><surname>Kuwano</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Uehara</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2014</year><volume>34</volume><fpage>2246</fpage><lpage>2253</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.114.303715</pub-id><pub-id pub-id-type="pmid">25104799</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Ruotolo</surname><given-names>G</given-names></name><name><surname>Brewer</surname><given-names>HB</given-names></name><name><surname>Kane</surname><given-names>JP</given-names></name><name><surname>Wang</surname><given-names>MD</given-names></name><name><surname>Krueger</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib</article-title><source>J Am Coll Cardiol</source><year>2015</year><volume>66</volume><fpage>2201</fpage><lpage>2210</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2015.09.013</pub-id><pub-id pub-id-type="pmid">26564598</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>MH</given-names></name><name><surname>Voogt</surname><given-names>J</given-names></name><name><surname>Luchoomun</surname><given-names>J</given-names></name><name><surname>Decaris</surname><given-names>J</given-names></name><name><surname>Killion</surname><given-names>S</given-names></name><name><surname>Boban</surname><given-names>D</given-names></name><etal/></person-group><article-title>Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans</article-title><source>Atherosclerosis</source><year>2013</year><volume>230</volume><fpage>322</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2013.08.006</pub-id><pub-id pub-id-type="pmid">24075764</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uto-Kondo</surname><given-names>H</given-names></name><name><surname>Ayaori</surname><given-names>M</given-names></name><name><surname>Sotherden</surname><given-names>GM</given-names></name><name><surname>Nakaya</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Yogo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ezetimibe enhances macrophage reverse cholesterol transport in hamsters: contribution of hepato-biliary pathway</article-title><source>Biochim Biophys Acta</source><year>1841</year><volume>2014</volume><fpage>1247</fpage><lpage>1255</lpage></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aharoni</surname><given-names>S</given-names></name><name><surname>Aviram</surname><given-names>M</given-names></name><name><surname>Fuhrman</surname><given-names>B</given-names></name></person-group><article-title>Paraoxonase 1 (PON1) reduces macrophage inflammatory responses</article-title><source>Atherosclerosis</source><year>2013</year><volume>228</volume><fpage>353</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2013.03.005</pub-id><pub-id pub-id-type="pmid">23582715</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Riwanto</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Levison</surname><given-names>BS</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex</article-title><source>J Clin Invest</source><year>2013</year><volume>123</volume><fpage>3815</fpage><lpage>3828</lpage><pub-id pub-id-type="doi">10.1172/JCI67478</pub-id><pub-id pub-id-type="pmid">23908111</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>WJ</given-names></name><name><surname>Mahlberg</surname><given-names>FH</given-names></name><name><surname>Rothblat</surname><given-names>GH</given-names></name><name><surname>Phillips</surname><given-names>MC</given-names></name></person-group><article-title>Cholesterol transport between cells and high-density lipoproteins</article-title><source>Biochim Biophys Acta</source><year>1991</year><volume>1085</volume><fpage>273</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/0005-2760(91)90132-2</pub-id><pub-id pub-id-type="pmid">1911862</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabresi</surname><given-names>L</given-names></name><name><surname>Franceschini</surname><given-names>G</given-names></name><name><surname>Sirtori</surname><given-names>CR</given-names></name><name><surname>De Palma</surname><given-names>A</given-names></name><name><surname>Saresella</surname><given-names>M</given-names></name><name><surname>Ferrante</surname><given-names>P</given-names></name><etal/></person-group><article-title>Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins</article-title><source>Biochem Biophys Res Commun</source><year>1997</year><volume>238</volume><fpage>61</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1997.7236</pub-id><pub-id pub-id-type="pmid">9299452</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>MC</given-names></name><name><surname>Mendez</surname><given-names>AJ</given-names></name><name><surname>Wolf</surname><given-names>AC</given-names></name><name><surname>Knopp</surname><given-names>RH</given-names></name></person-group><article-title>Characterization of apolipoprotein A-I- and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling Tangier disease and their effects on intracellular cholesterol efflux</article-title><source>J Clin Invest</source><year>1993</year><volume>91</volume><fpage>522</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1172/JCI116231</pub-id><pub-id pub-id-type="pmid">8432861</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>H</given-names></name><name><surname>Yokoyama</surname><given-names>S</given-names></name></person-group><article-title>Interaction of free apolipoproteins with macrophages. Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol</article-title><source>J Biol Chem</source><year>1991</year><volume>266</volume><fpage>3080</fpage><lpage>3086</lpage><pub-id pub-id-type="pmid">1993681</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remaley</surname><given-names>AT</given-names></name><name><surname>Stonik</surname><given-names>JA</given-names></name><name><surname>Demosky</surname><given-names>SJ</given-names></name><name><surname>Neufeld</surname><given-names>EB</given-names></name><name><surname>Bocharov</surname><given-names>AV</given-names></name><name><surname>Vishnyakova</surname><given-names>TG</given-names></name><etal/></person-group><article-title>Apolipoprotein specificity for lipid efflux by the human ABCAI transporter</article-title><source>Biochem Biophys Res Commun</source><year>2001</year><volume>280</volume><fpage>818</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2000.4219</pub-id><pub-id pub-id-type="pmid">11162594</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sankaranarayanan</surname><given-names>S</given-names></name><name><surname>Oram</surname><given-names>JF</given-names></name><name><surname>Asztalos</surname><given-names>BF</given-names></name><name><surname>Vaughan</surname><given-names>AM</given-names></name><name><surname>Lund-Katz</surname><given-names>S</given-names></name><name><surname>Adorni</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux</article-title><source>J Lipid Res</source><year>2009</year><volume>50</volume><fpage>275</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1194/jlr.M800362-JLR200</pub-id><pub-id pub-id-type="pmid">18827283</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westerterp</surname><given-names>M</given-names></name><name><surname>Berbee</surname><given-names>JF</given-names></name><name><surname>Pires</surname><given-names>NM</given-names></name><name><surname>van Mierlo</surname><given-names>GJ</given-names></name><name><surname>Kleemann</surname><given-names>R</given-names></name><name><surname>Romijn</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Apolipoprotein C-I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice</article-title><source>Circulation</source><year>2007</year><volume>116</volume><fpage>2173</fpage><lpage>2181</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.693382</pub-id><pub-id pub-id-type="pmid">17967778</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cudaback</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yoo</surname><given-names>T</given-names></name><name><surname>Montine</surname><given-names>KS</given-names></name><name><surname>Craft</surname><given-names>S</given-names></name><etal/></person-group><article-title>Apolipoprotein C-I is an APOE genotype-dependent suppressor of glial activation</article-title><source>J Neuroinflammation</source><year>2012</year><volume>9</volume><fpage>192</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-9-192</pub-id><pub-id pub-id-type="pmid">22883744</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petropoulou</surname><given-names>PI</given-names></name><name><surname>Berbee</surname><given-names>JF</given-names></name><name><surname>Theodoropoulos</surname><given-names>V</given-names></name><name><surname>Hatziri</surname><given-names>A</given-names></name><name><surname>Stamou</surname><given-names>P</given-names></name><name><surname>Karavia</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Lack of LCAT reduces the LPS-neutralizing capacity of HDL and enhances LPS-induced inflammation in mice</article-title><source>Biochim Biophys Acta</source><year>1852</year><volume>2015</volume><fpage>2106</fpage><lpage>2115</lpage></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jong</surname><given-names>MC</given-names></name><name><surname>Hofker</surname><given-names>MH</given-names></name><name><surname>Havekes</surname><given-names>LM</given-names></name></person-group><article-title>Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3</article-title><source>Arterioscler Thromb Vasc Biol</source><year>1999</year><volume>19</volume><fpage>472</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.19.3.472</pub-id><pub-id pub-id-type="pmid">10073946</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pamir</surname><given-names>N</given-names></name><name><surname>Hutchins</surname><given-names>P</given-names></name><name><surname>Ronsein</surname><given-names>G</given-names></name><name><surname>Vaisar</surname><given-names>T</given-names></name><name><surname>Reardon</surname><given-names>CA</given-names></name><name><surname>Getz</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Proteomic analysis of HDL from inbred mouse strains implicates APOE associated with HDL in reduced cholesterol efflux capacity via the ABCA1 pathway</article-title><source>J Lipid Res</source><year>2016</year><volume>57</volume><fpage>246</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">26673204</pub-id></element-citation></ref></ref-list></back></article>